Skip to main content

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 4 of 12

  1. Colorectal cancer has been found to be attenuated either with prophylactic manipulation of gut microbiome with probiotics or celecoxib, a non-steroidal anti-inflammatory drug mainly by suppressing early pro-ca...

    Authors: Leila Kaeid Sharaf, Mridul Sharma, Deepika Chandel and Geeta Shukla

    Citation: BMC Cancer 2018 18:1111

    Content type: Research article

    Published on:

  2. Cholangiocarcinoma, or bile duct cancer, is a gastrointestinal cancer with limited therapeutic options and a poor outcome. Studies have revealed that some major driver genes are associated with cholangiocarcin...

    Authors: Haibo Mou, Lanfang Yu, Qin Liao, Xuehua Hou, Yinfang Wu, Qiang Cui, Na Yan, Ruobing Ma, Lingjian Wang, Ming Yao and Kai Wang

    Citation: BMC Cancer 2018 18:1105

    Content type: Case report

    Published on:

  3. In acute lymphoblastic leukemia (ALL), the presence of minimal residual disease (MRD) after induction/consolidation chemotherapy is a strong prognostic factor for subsequent relapse and mortality. Accordingly,...

    Authors: Arnaud Pigneux, Pau Montesinos, Ze Cong, Xinke Zhang, Anja K. Pownell, Heather Wieffer, Jan McKendrick and Monika Brüggemann

    Citation: BMC Cancer 2018 18:1100

    Content type: Research article

    Published on:

  4. Colorectal cancer is the third most common cancer worldwide; and in 40% of all cases, KRAS4b-activating mutations occur. KRAS4b is transported by phosphodiesterase-6δ (PDEδ) to the plasma membrane, where it ge...

    Authors: Pedro Cruz-Nova, Michael Schnoor, José Correa-Basurto, Martiniano Bello, Paola Briseño-Diaz, Arturo Rojo-Domínguez, Carlos M. Ortiz-Mendoza, Jorge Guerrero-Aguirre, Francisco J. García-Vázquez, Rosaura Hernández-Rivas, María del Rocío Thompson-Bonilla and Miguel Vargas

    Citation: BMC Cancer 2018 18:1056

    Content type: Research article

    Published on:

  5. Docosahexaenoic acid (DHA) is a long chain n-3 polyunsaturated fatty acid that has anticancer activity. Heme oxygenase 1 (HO-1) is a potential therapeutic target due to its cytoprotective activity in cancer ce...

    Authors: Yang Jiao, Tanya Watts, Jing Xue, Bethany Hannafon and Wei-Qun Ding

    Citation: BMC Cancer 2018 18:1042

    Content type: Research article

    Published on:

  6. The chemotherapy resistance and toxicity of chemotherapy are major problems in breast cancer treatment. However, candidate biomarkers for predicting clinical outcomes and better prognosis remain lacking.

    Authors: Lu Chen, Huijie Qi, Liudi Zhang, Haixia Li, Jie Shao, Haifei Chen, Mingkang Zhong, Xiaojin Shi, Ting Ye and Qunyi Li

    Citation: BMC Cancer 2018 18:1038

    Content type: Research article

    Published on:

  7. The RAS/RAF/MEK/ERK pathway is one of the most downregulated pathway in cancer. Inhibitors of RAF and MEK have established clinical use while ERK inhibitors recently faced the clinic. We aimed to generate resi...

    Authors: Alice Iezzi, Elisa Caiola, Arianna Scagliotti and Massimo Broggini

    Citation: BMC Cancer 2018 18:1028

    Content type: Research article

    Published on:

  8. The Insulin-like growth factor (IGF) pathway plays a role in tumour development and progression. In vivo, IGF1 activity is regulated by the IGF binding proteins (IGFBPs). IGFBP4 inhibits the activity of IGF1 b...

    Authors: Y. E. Smith, S. Toomey, S. Napoletano, G. Kirwan, C. Schadow, A. J. Chubb, J. H. Mikkelsen, C. Oxvig and J. H. Harmey

    Citation: BMC Cancer 2018 18:1016

    Content type: Research article

    Published on:

  9. Rigors are a significant adverse event during interleukin-2 (IL2) therapy for metastatic melanoma and renal cell carcinoma. Meperidine has been a mainstay for rigor prophylaxis but there is a paucity of data r...

    Authors: Brian Khong, Benjamin O. Lawson, Junjie Ma, Cheryl McGovern, Joan K. Van Atta, Abhijit Ray and Hung T. Khong

    Citation: BMC Cancer 2018 18:1007

    Content type: Research article

    Published on:

  10. Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Neve...

    Authors: Roland Christian Schelker, Wolfgang Herr, Albrecht Reichle and Martin Vogelhuber

    Citation: BMC Cancer 2018 18:1000

    Content type: Research article

    Published on:

  11. The tumour microenvironment conferred by mesenchymal stem cells (MSCs) plays a key role in tumour development and progression. We previously determined that platelet-activating factor receptor (PAFR) was overe...

    Authors: Tong Gao, Yi Yu, Qing Cong, Yisheng Wang, Mingming Sun, Liangqing Yao, Congjian Xu and Wei Jiang

    Citation: BMC Cancer 2018 18:999

    Content type: Research article

    Published on:

  12. Conventional chemotherapy is commonly used to treat non-small cell lung cancer (NSCLC) however it increases therapeutic resistance. In contrast, metronomic chemotherapy (MET) is based on frequent drug administ...

    Authors: Rong-Sheng Qin, Zhen-Hua Zhang, Neng-Ping Zhu, Fei Chen, Qian Guo, Hao-Wen Hu, Shao-Zhi Fu, Shan-Shan Liu, Yue Chen, Juan Fan and Yun-Wei Han

    Citation: BMC Cancer 2018 18:967

    Content type: Research article

    Published on:

  13. Oligometastases refer to a state of disease where cancer has spread beyond the primary site, but is not yet widely metastatic, often defined as 1–3 or 1–5 metastases in number. Stereotactic ablative radiothera...

    Authors: Robert Olson, Mitchell Liu, Alanah Bergman, Sonya Lam, Fred Hsu, Benjamin Mou, Tanya Berrang, Ante Mestrovic, Nick Chng, Derek Hyde, Quinn Matthews, Chad Lund, Daniel Glick, Howard Pai, Parminder Basran, Hannah Carolan…

    Citation: BMC Cancer 2018 18:954

    Content type: Study protocol

    Published on:

  14. Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer. Besides their anti-tumour efficacy, several PKIs have also...

    Authors: Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli and Jürgen Grünberg

    Citation: BMC Cancer 2018 18:922

    Content type: Research article

    Published on:

  15. Soft tissue sarcomas are a heterogeneous and rare group of solid tumors of mesenchymal origin that can arise anywhere in the body. Although surgical resection is the mainstay of treatment for patients with loc...

    Authors: Emily Z. Keung, Alexander J. Lazar, Keila E. Torres, Wei-Lien Wang, Janice N. Cormier, B. Ashleigh Guadagnolo, Andrew J. Bishop, Heather Lin, Kelly K. Hunt, Justin Bird, Valerae O. Lewis, Shreyaskumar R. Patel, Jennifer A. Wargo, Neeta Somaiah and Christina L. Roland

    Citation: BMC Cancer 2018 18:913

    Content type: Study protocol

    Published on:

  16. There is an urgent need for more novel and efficacious therapeutic agents and strategies for the treatment of ovarian cancer - one of the most formidable female malignancies. These approaches should be based o...

    Authors: Vsevolod I. Kiselev, Levon A. Ashrafyan, Ekaterina L. Muyzhnek, Evgeniya V. Gerfanova, Irina B. Antonova, Olga I. Aleshikova and Fazlul H. Sarkar

    Citation: BMC Cancer 2018 18:904

    Content type: Research article

    Published on:

  17. Although our previous study revealed lumbar punctured resveratrol could remarkably prolong the survival of rats bearing orthotopic glioblastomas, it also suggested the administration did not completely suppres...

    Authors: Xue Song, Xiao-Hong Shu, Mo-Li Wu, Xu Zheng, Bin Jia, Qing-You Kong, Jia Liu and Hong Li

    Citation: BMC Cancer 2018 18:871

    Content type: Research article

    Published on:

  18. Melanoma is one of the most invasive and aggressive types of cancer with a very poor prognosis. Surgery remains the most efficient treatment prior melanoma invasion and metastasis formation. However, therapy b...

    Authors: Myra O. Villareal, Yuki Sato, Kyoko Matsuyama and Hiroko Isoda

    Citation: BMC Cancer 2018 18:856

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Cancer 2018 18:902

  19. Pleomorphic liposarcoma (PLPS) is a rare, heterogeneous and an aggressive variant of liposarcoma. Therefore, individualized therapy is urgently needed. Our recent reports suggest that trabectedin (TRAB) is eff...

    Authors: Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kei Kawaguchi, Kentaro Igarashi, Kentaro Miyake, Masuyo Miyake, Yunfeng Li, Scott D. Nelson, Sarah M. Dry, Arun S. Singh, Tara A. Russell, Irmina Elliott, Shree Ram Singh, Fuminori Kanaya, Fritz C. Eilber…

    Citation: BMC Cancer 2018 18:840

    Content type: Research article

    Published on:

  20. Colorectal cancer (CRC) remains a leading cause of death worldwide. Utilizing cisplatin in CRC is correlated with severe adverse effects and drug-resistance. Combined anticancer drug-treatment, along with, the...

    Authors: Mona M. Saber, Abdulaziz M. Al-mahallawi, Noha N. Nassar, Björn Stork and Samia A. Shouman

    Citation: BMC Cancer 2018 18:822

    Content type: Research article

    Published on:

  21. The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan.

    Authors: Diego Tosi, Esther Pérez-Gracia, Salima Atis, Nadia Vié, Eve Combès, Mélissa Gabanou, Christel Larbouret, Marta Jarlier, Caroline Mollevi, Adeline Torro, Maguy Del Rio, Pierre Martineau and Céline Gongora

    Citation: BMC Cancer 2018 18:812

    Content type: Research article

    Published on:

  22. The Musashi (MSI) family of RNA-binding proteins is best known for the role in post-transcriptional regulation of target mRNAs. Elevated MSI1 levels in a variety of human cancer are associated with up-regulati...

    Authors: Lan Lan, Hao Liu, Amber R. Smith, Carl Appelman, Jia Yu, Sarah Larsen, Rebecca T. Marquez, Xiaoqing Wu, Frank Y. Liu, Philip Gao, Ragul Gowthaman, John Karanicolas, Roberto N. De Guzman, Steven Rogers, Jeffrey Aubé, Kristi L. Neufeld…

    Citation: BMC Cancer 2018 18:809

    Content type: Research article

    Published on:

  23. Sirtuin 2 (SIRT2) is a member of the sirtuin family, nicotinamide adenine dinucleotide+-dependent deacylases, which participates in modulation of cell cycle control, neurodegeneration, and tumorigenesis. SIRT2 ex...

    Authors: Tomohiro Kozako, Paolo Mellini, Takeo Ohsugi, Akiyoshi Aikawa, Yu-ichiro Uchida, Shin-ichiro Honda and Takayoshi Suzuki

    Citation: BMC Cancer 2018 18:791

    Content type: Research article

    Published on:

  24. Quizartinib, an inhibitor of class III receptor tyrosine kinases (RTKs), is currently in phase 3 development for the treatment of acute myeloid leukemia (AML) bearing internal tandem duplications in the FLT3 gene...

    Authors: Kyriakos P. Papadopoulos, Eytan Ben-Ami, Amita Patnaik, Denise Trone, Jianke Li and George D. Demetri

    Citation: BMC Cancer 2018 18:790

    Content type: Research article

    Published on:

  25. Disulfiram (DS), an antialcoholism medicine, demonstrated strong anticancer activity in the laboratory but did not show promising results in clinical trials. The anticancer activity of DS is copper dependent. ...

    Authors: Kate Butcher, Vinodh Kannappan, Rajagopal Sharada Kilari, Mark R. Morris, Christopher McConville, Angel L. Armesilla and Weiguang Wang

    Citation: BMC Cancer 2018 18:753

    Content type: Research article

    Published on:

  26. Targeted therapy has always been the focus in developing therapeutic approaches in cancer, especially in the treatment of acute myeloid leukemia (AML). A new small molecular inhibitor, JQ1, targeting BRD4, whi...

    Authors: Yafeng Zhou, Jianbiao Zhou, Xiao Lu, Tuan-Zea Tan and Wee-Joo Chng

    Citation: BMC Cancer 2018 18:731

    Content type: Research article

    Published on:

  27. High HOX gene expression has been described in many cancers, including oral squamous cell carcinoma and the functional roles of these genes are gradually being understood. The pattern of overexpression suggest...

    Authors: Christopher Platais, Raghu Radhakrishnan, Sven Niklander Ebensperger, Richard Morgan, Daniel W. Lambert and Keith D. Hunter

    Citation: BMC Cancer 2018 18:723

    Content type: Research article

    Published on:

  28. Sentinel lymph node metastasis is a common and early event in the metastatic process of head and neck squamous cell carcinoma (HNSCC) and is the most powerful prognostic factor for survival of HNSCC patients. 3-O

    Authors: Jeon Hwang-Bo, Mun Gyeong Bae, Jong-Hwa Park and In Sik Chung

    Citation: BMC Cancer 2018 18:714

    Content type: Research article

    Published on:

  29. Cancer cells require increased levels of nutrients such as amino acids to sustain their rapid growth. In particular, leucine and glutamine have been shown to be important for growth and proliferation of some b...

    Authors: Michelle van Geldermalsen, Lake-Ee Quek, Nigel Turner, Natasha Freidman, Angel Pang, Yi Fang Guan, James R. Krycer, Renae Ryan, Qian Wang and Jeff Holst

    Citation: BMC Cancer 2018 18:689

    Content type: Research article

    Published on:

  30. We previously showed that knockdown of nuclear factor E2-related factor 2 (Nrf2) resulted in suppression of hepatitis C virus (HCV) infection. In this study, whether brusatol, an Nrf2 inhibitor, has dual anti-...

    Authors: Yuko Murakami, Kazuo Sugiyama, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Keisuke Ojiro, Po-sung Chu, Nobuhito Taniki, Yoshimasa Saito, Toshiaki Teratani, Yuzo Koda, Takahiro Suzuki, Kyoko Saito, Masayoshi Fukasawa, Masanori Ikeda, Nobuyuki Kato, Takanori Kanai…

    Citation: BMC Cancer 2018 18:680

    Content type: Research article

    Published on:

  31. Cervical dysplasia (cervical intraepithelial neoplasia (CIN)) is caused by Human Papillomavirus (HPV) and is most common in women of reproductive age. Current treatment of moderate to severe CIN is surgical. T...

    Authors: A. J. M. van de Sande, M. M. Koeneman, C. G. Gerestein, A. J. Kruse, F. J. van Kemenade and H. J. van Beekhuizen

    Citation: BMC Cancer 2018 18:655

    Content type: Study protocol

    Published on:

  32. In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior. We performed a prospective, open-label, non-c...

    Authors: Masahiro Hatooka, Tomokazu Kawaoka, Hiroshi Aikata, Yuki Inagaki, Kei Morio, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Kazuo Awai, Keiichi Masaki, Koji Waki, Hirotaka Kohno, Hiroshi Kohno…

    Citation: BMC Cancer 2018 18:633

    Content type: Research article

    Published on:

  33. Indole-3-carbinol, derived from Cruciferous vegetables is an estrogen receptor antagonist considered a preventive agent that is naturally present in diet. There are no previous studies on its effects in human ...

    Authors: Asunción Martín-Ruiz, Laura Peña, Alfredo González-Gil, Lucía Teresa Díez-Córdova, Sara Cáceres and Juan Carlos Illera

    Citation: BMC Cancer 2018 18:626

    Content type: Research article

    Published on:

  34. Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. The disease recurrent rate is relatively high resulted in poor 5-year survival in advanced HCC. Cancer stem cells (...

    Authors: Wei-Chieh Huang, Shiao-Lin Tung, Yao-Li Chen, Po-Ming Chen and Pei-Yi Chu

    Citation: BMC Cancer 2018 18:609

    Content type: Research article

    Published on:

  35. Repurposing existing medications for antineoplastic purposes can provide a safe, cost-effective, and efficacious means to further augment available cancer care. Clinical and preclinical studies suggest a role ...

    Authors: Jennifer M. Knight, Stephanie A. Kerswill, Parameswaran Hari, Steve W. Cole, Brent R. Logan, Anita D’Souza, Nirav N. Shah, Mary M. Horowitz, Melinda R. Stolley, Erica K. Sloan, Karen E. Giles, Erin S. Costanzo, Mehdi Hamadani, Saurabh Chhabra, Binod Dhakal and J. Douglas Rizzo

    Citation: BMC Cancer 2018 18:593

    Content type: Research article

    Published on:

  36. There is increasing appreciation that non-cancer cells within the tumour microenvironment influence cancer progression and anti-cancer drug efficacy. For metastatic prostate cancer (PCa), the bone marrow micro...

    Authors: Eman Mosaad, Karen Chambers, Kathryn Futrega, Judith Clements and Michael Robert Doran

    Citation: BMC Cancer 2018 18:592

    Content type: Research article

    Published on:

  37. Patients with cancer develop endothelial dysfunction and subsequently display a higher risk of cardiovascular events. The aim of the present work was to examine changes in nitric oxide (NO)- and prostacyclin (PGI

    Authors: E. Buczek, A. Denslow, L. Mateuszuk, B. Proniewski, T. Wojcik, B. Sitek, A. Fedorowicz, A. Jasztal, E. Kus, A. Chmura- Skirlinska, R. Gurbiel, J. Wietrzyk and S. Chlopicki

    Citation: BMC Cancer 2018 18:582

    Content type: Research article

    Published on:

  38. All known mechanisms of apoptosis induced by resveratrol act through cell cycle arrest and changes in mitochondrial membrane potential. It is currently unknown whether resveratrol-induced apoptosis is associat...

    Authors: Yingying Fan, Jen-Fu Chiu, Jing Liu, Yan Deng, Cheng Xu, Jun Zhang and Guanwu Li

    Citation: BMC Cancer 2018 18:581

    Content type: Research article

    Published on:

  39. Previous studies showed sanguinarine induced apoptosis in CRC cells but did not define the underlying mechanisms. The purpose of this work was to determine the in vivo and in vitro effects of sanguinarine on C...

    Authors: Xianling Gong, Zhihong Chen, Qinrui Han, Chunhui Chen, Linlin Jing, Yawei Liu, Liang Zhao, Xueqing Yao and Xuegang Sun

    Citation: BMC Cancer 2018 18:578

    Content type: Research article

    Published on:

  40. Neuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB will have relapse and therefore long-term event free survival is very minimal. We have rep...

    Authors: Selvi Kunnimalaiyaan, Victoriana K. Schwartz, Iris Alao Jackson, T. Clark Gamblin and Muthusamy Kunnimalaiyaan

    Citation: BMC Cancer 2018 18:560

    Content type: Research article

    Published on:

  41. Currently, there are no available targeted therapy options for non-V600 BRAF mutated tumors. The aim of this study was to investigate the effects of RAF and MEK concurrent inhibition on tumor growth, migration...

    Authors: Eszter Molnár, Dominika Rittler, Marcell Baranyi, Michael Grusch, Walter Berger, Balázs Döme, József Tóvári, Clemens Aigner, József Tímár, Tamás Garay and Balázs Hegedűs

    Citation: BMC Cancer 2018 18:542

    Content type: Research article

    Published on:

  42. We previously reported that clioquinol acts as a zinc ionophore and inhibits the NF-κB signalling pathway. Other research has demonstrated that zinc deficiency plays a vital role in the occurrence and developm...

    Authors: Shan Lu, Yuan Ke, Chaoyan Wu, Yahua Zhong, Conghua Xie, Yunfeng Zhou, Fuxiang Zhou and Haijun Yu

    Citation: BMC Cancer 2018 18:448

    Content type: Research article

    Published on:

  43. Previous studies have suggested that metformin may be useful for preventing and treating endometrial cancer (EC), while the results have been inconsistent. This systematic review and meta-analysis aimed to inv...

    Authors: Danxia Chu, Jie Wu, Kaili Wang, Mengling Zhao, Chunfang Wang, Liuxia Li and Ruixia Guo

    Citation: BMC Cancer 2018 18:438

    Content type: Research article

    Published on:

  44. Mammary cancer is highly prevalent in dogs and cats and results in a poor prognosis due to critically lacking viable treatment options. Recent human and mouse studies have suggested that inhibiting peptidyl ar...

    Authors: Melissa M. Ledet, Robyn Anderson, Rebecca Harman, Aaron Muth, Paul R. Thompson, Scott A. Coonrod and Gerlinde R. Van de Walle

    Citation: BMC Cancer 2018 18:412

    Content type: Research article

    Published on:

  45. Brucea javanica oil emulsion (BJOE) is traditional Chinese medicine with implicated anti-tumor activity, which has been used for treating lung cancer in China. The aim of this investigation was to evaluate the...

    Authors: Dai Fuhong, Gao Xiang, Li Haiying, Wang Jiangye, Gao Xueming and Chai Wenxiao

    Citation: BMC Cancer 2018 18:411

    Content type: Research article

    Published on: